Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  exemestane
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 68 for your search:
Start Over
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: A5991089, NCT01047358
Pharmacology of Adjuvant Hormonotherapy in Breast Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 09 SEIN 09, NCT01127295
Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11 SEIN 09, NCT01553903
Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11SEIN12, NCT01612871
An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001YGB11, 2012-003689-41, NCT01743560
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: CDR0000456382, ACOSOG-Z1031, CALGB-ACOSOG-Z1031, SDC1, NCT00265759
Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Other
Protocol IDs: EORTC-10951, PHARMACIA-EORTC-10951, NCT00002777
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: Premenopausal
Sponsor: NCI, Other
Protocol IDs: CDR0000316456, IBCSG 24-02, BIG 2-02, CALGB-IBCSG 24-02, CAN-NCIC-IBCSG 24-02, NCCTG-IBCSG 24-02, NSABP-IBCSG 24-02, SWOG-IBCSG 24-02, NABCI-IBCSG 24-02, UCLA-0403024-01, EU-20334, EUDRACT-2004-000166-13, NCT00066690
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: Premenopausal
Sponsor: NCI, Other
Protocol IDs: IBCSG 25-02, CDR0000316458, BIG-3-02, NABCI-IBCSG-25-02, EU-20347, EUDRACT-2004-000168-28, NCT00066703
The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9238IL/0048, EFECT, D6997C00048, NCT00065325
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Status: Closed
Age: 35 and over
Sponsor: Other
Protocol IDs: MAP3, CAN-NCIC-MAP3, PFIZER-EXEAPO-0028-150, ExCel, CDR0000363802, NCT00083174
Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A5991048, NCT00143390
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
Phase: Phase III
Type: Treatment
Status: Completed
Age: 50 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 971-ONC-0028-081, A5991026, NCT00036270
Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Other
Protocol IDs: CDR0000448616, ICR-CTSU-SOFEA, EU-20531, SSA-04Q200635, ISRCTN44195747, MREC-03677, EUDRACT-2004-000093-30, NCT00253422
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 30 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 96-OEXE-031, A5991012, NCT00038467
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Closed
Age: 18 to 75
Sponsor: NCI
Protocol IDs: NCI-2009-00707, CDR0000472066, ECOG-PACCT-1, PACCT-1, U10CA180820, U10CA021115, NCT00310180
Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001Y2301, 2008-008698-69, NCT00863655
Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)
Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: 9238UK/0005, NCT00944918
Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen
Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: NSABP B-33, CDR0000068640, ECOG-NSABP-B-33, NCT00016432
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: MA27, CAN-NCIC-MA27, NCCTG-MA27, CALGB-CAN-NCIC-MA27, ECOG-CAN-NCIC-MA27, SWOG-CAN-NCIC-MA27, IBCSG-30-04, EUDRACT-2005-001893-28, CDR0000316325, CAN-NCIC-MA27-COMPANION, NCIC-MA.27, NCT00066573
4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001JDE49, NCT01626222
Start Over